Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab

• 1 Eastern Health, Melbourne, VIC
• 2 Monash University, Melbourne, VIC
• 3 St Vincent’s Hospital Sydney, Sydney, NSW
• 4 University of Sydney, Sydney, NSW
• 5 Fiona Stanley Hospital, Perth, WA

---

• 1. Lim D, Bandiera R, Handsley E. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab [letter]. Med J Aus 2021; 215: 000–000.
• 2. Haifer C, Srinivasan A, An Y‐K, et al. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Med J Aus 2021; 214: 128–133. https://www.mja.com.au/journal/2021/214/3/switching-australian-patients-moderate-severe-inflammatory-bowel-disease
• 3. Weise M, Bielsky M‐C, De Smet K, et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111–5117.
• 4. Lemery SJ, Ricci MS, Keegan P, et al. FDA’s approach to regulating biosimilars. Clin Cancer Res 2017; 23: 1882–1885.
• 5. Pharmaceutical Benefits Scheme. Reimbursement of biosimilar medicines. https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2015-04/2015-04-biosimilars.pdf (viewed May 2021).
• 6. Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States? BioDrugs 2020; 34: 723–732.